Clobazam (Onfi) vs Ganaxolone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Clobazam (Onfi)

Marketed by Lundbeck LLC and partners

Approved in Epilepsysmall molecule
Reliable signal

NCT00518713 · Phase 3 · completed

The study randomly assigned 238 participants to low-, medium-, or high-dose clobazam or placebo, with participants, care providers, and investigators masked to treatment. Its clinical primary endpoint—percent reduction in drop seizures—was statistically better than placebo for all three doses, supporting a strong evidence grade.

Reported efficacy

Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) (met)

Result source: NCT00518713

Ganaxolone

Marketed by Immedica Pharma AB

Approved in Epilepsysmall molecule
Partial signal

NCT01963208 · Phase 3 · completed

The primary phase was well controlled, with randomized quadruple blinding, placebo comparison, and 350 analyzed participants, and it used the clinical endpoint of change in seizure frequency. However, the primary endpoint was missed: the difference between ganaxolone and placebo was not statistically significant (p=0.1788), so the study provides well-designed but inconclusive evidence.

Reported efficacy

Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes); Percentage of Participants With no Progression to Intravenous (IV) Anesthesia for 36 Hours Following Investigational Product (IP) Initiation (Up to 36 hours after IP initiation); Number of Participants With Treatment Emergent Adverse Events (Up to 4 weeks after IP initiation): Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741) (mixed)

Result source: NCT04391569

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointClobazam (Onfi)Ganaxolone
Seizure frequency, % change—Not reported-7.5% vs 13.6%−21.1 vs placebowk 4 · n 64NCT05323734
4 other results
  • -61.5% vs -24.0% wk 17 · n 10 · Phase 2 · primary NCT03865732
  • -17.6% vs 2.0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • -12.1% vs 4.6% wk 10 · n 95 · Phase 2 · secondary NCT00465517
  • -35.9% vs -18.7% wk 17 · n 6 · Phase 2 · secondary NCT03865732
50% responder rate—Not reported18.8% vs 12.3%+6.5 vs placebowk 16 · n 64NCT05323734
3 other results
  • 23.5% vs 14.3% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 25.5% vs 12.2% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 50% vs 36.4% wk 17 · n 10 · Phase 2 · secondary NCT03865732
Seizure freedom—Not reported0% vs 2.2%−2.2 vs placebowk 10 · n 95NCT00465517
2 other results
  • 1% vs 0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 16.8% vs 8.3% wk 2 · n 95 · Phase 2 · secondary NCT00465517

Seizure frequency, % change

Clobazam (Onfi)
—Not reported
Ganaxolone
-7.5% vs 13.6%−21.1 vs placebowk 4 · n 64NCT05323734
4 other results
  • -61.5% vs -24.0% wk 17 · n 10 · Phase 2 · primary NCT03865732
  • -17.6% vs 2.0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • -12.1% vs 4.6% wk 10 · n 95 · Phase 2 · secondary NCT00465517
  • -35.9% vs -18.7% wk 17 · n 6 · Phase 2 · secondary NCT03865732

50% responder rate

Clobazam (Onfi)
—Not reported
Ganaxolone
18.8% vs 12.3%+6.5 vs placebowk 16 · n 64NCT05323734
3 other results
  • 23.5% vs 14.3% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 25.5% vs 12.2% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 50% vs 36.4% wk 17 · n 10 · Phase 2 · secondary NCT03865732

Seizure freedom

Clobazam (Onfi)
—Not reported
Ganaxolone
0% vs 2.2%−2.2 vs placebowk 10 · n 95NCT00465517
2 other results
  • 1% vs 0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 16.8% vs 8.3% wk 2 · n 95 · Phase 2 · secondary NCT00465517
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Clobazam (Onfi): 4 of 4 rows · Ganaxolone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricClobazam (Onfi)Ganaxolone
Dropout rate
30.5%high dosea
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 4 more results
13.8%low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
27.4%medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
29.6%
NCT01160770 · Phase 3 · monotherapy
10%
NCT03371836 · Phase 4 · registry result, not featured evidence
4.2%Double Blind: Cohort 1 - Ganaxolonb
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
24.6%Double Blind: Cohort 2 - Ganaxolon
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Ganaxolone in Double-b
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Placebo in Double-blin
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
41.2%
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
14.1%
NCT05323734 · Phase 3 · registry result, not featured evidence
10%
NCT03865732 · Phase 2 · registry result, not featured evidence
12.5%High
NCT03350035 · Phase 2 · registry result, not featured evidence
40%Low
NCT03350035 · Phase 2 · registry result, not featured evidence
0%Medium
NCT03350035 · Phase 2 · registry result, not featured evidence
42.9%CDKL5
NCT02358538 · Phase 2 · registry result, not featured evidence
100%CSWS
NCT02358538 · Phase 2 · registry result, not featured evidence
50%Lennox-Gastaut
NCT02358538 · Phase 2 · registry result, not featured evidence
45.5%PCDH19
NCT02358538 · Phase 2 · registry result, not featured evidence
95.1%
NCT00512317 · Phase 2 · registry result, not featured evidence
36.4%
NCT01002820 · Phase 2 · registry result, not featured evidence
12.2%
NCT00465517 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—high dosea
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 4 more results
—low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
—medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
3.7%
NCT01160770 · Phase 3 · monotherapy
—
NCT03371836 · Phase 4 · registry result, not featured evidence
4.2%Double Blind: Cohort 1 - Ganaxolonb
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
16.8%Double Blind: Cohort 2 - Ganaxolon
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Ganaxolone in Double-b
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Placebo in Double-blin
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
7.8%
NCT05323734 · Phase 3 · registry result, not featured evidence
10%
NCT03865732 · Phase 2 · registry result, not featured evidence
—High
NCT03350035 · Phase 2 · registry result, not featured evidence
—Low
NCT03350035 · Phase 2 · registry result, not featured evidence
—Medium
NCT03350035 · Phase 2 · registry result, not featured evidence
0%CDKL5
NCT02358538 · Phase 2 · registry result, not featured evidence
50%CSWS
NCT02358538 · Phase 2 · registry result, not featured evidence
10%Lennox-Gastaut
NCT02358538 · Phase 2 · registry result, not featured evidence
18.2%PCDH19
NCT02358538 · Phase 2 · registry result, not featured evidence
10.6%
NCT00512317 · Phase 2 · registry result, not featured evidence
9.1%
NCT01002820 · Phase 2 · registry result, not featured evidence
7.1%
NCT00465517 · Phase 2 · registry result, not featured evidence
Serious AEs
8.5%high dosea
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 4 more results
5.2%low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
9.7%medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
43.1%
NCT01160770 · Phase 3 · monotherapy
—
NCT03371836 · Phase 4 · registry result, not featured evidence
0%Double Blind: Cohort 1 - Ganaxolonb
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
5%Double Blind: Cohort 2 - Ganaxolon
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
7.6%Open Label: Ganaxolone in Double-b
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
6.9%Open Label: Placebo in Double-blin
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
37.3%
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
7.8%
NCT05323734 · Phase 3 · registry result, not featured evidence
10%
NCT03865732 · Phase 2 · registry result, not featured evidence
25%High
NCT03350035 · Phase 2 · registry result, not featured evidence
40%Low
NCT03350035 · Phase 2 · registry result, not featured evidence
50%Medium
NCT03350035 · Phase 2 · registry result, not featured evidence
14.3%CDKL5
NCT02358538 · Phase 2 · registry result, not featured evidence
50%CSWS
NCT02358538 · Phase 2 · registry result, not featured evidence
20%Lennox-Gastaut
NCT02358538 · Phase 2 · registry result, not featured evidence
27.3%PCDH19
NCT02358538 · Phase 2 · registry result, not featured evidence
12.2%
NCT00512317 · Phase 2 · registry result, not featured evidence
9.1%
NCT01002820 · Phase 2 · registry result, not featured evidence
5.1%
NCT00465517 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
high dosea
somnolence 25.4% (placebo 11.9%)
lethargy 15.3% (placebo 5.1%)
aggression 13.6% (placebo 5.1%)
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 3 more results
low dose
pyrexia 17.2% (placebo 3.4%)
somnolence 15.5% (placebo 11.9%)
lethargy 10.3% (placebo 5.1%)
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
medium dose
somnolence 24.2% (placebo 11.9%)
drooling 12.9% (placebo 3.4%)
upper respiratory tract infection 12.9% (placebo 10.2%)
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
upper respiratory tract infection 28.1%
pyrexia 18%
somnolence 16.9%
NCT01160770 · Phase 3 · monotherapy
b
ataxia 12.5% (placebo 0%)
sedation 12.5% (placebo 0%)
somnolence 12.5% (placebo 9.5%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
somnolence 22.3% (placebo 9.5%)
dizziness 19% (placebo 0%)
fatigue 11.7% (placebo 0%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
somnolence 7.6% (placebo 9.5%)
fatigue 5.7% (placebo 0%)
headache 5.7% (placebo 0%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
somnolence 16.8% (placebo 9.5%)
dizziness 15.6% (placebo 0%)
fatigue 8.7% (placebo 0%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
hypotension 23.5% (placebo 16.3%)
urinary tract infection 19.6% (placebo 8.2%)
hypothermia 9.8% (placebo 4.1%)
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
somnolence 28.1% (placebo 16.9%)
pyrexia 15.6% (placebo 16.9%)
fatigue 14.1% (placebo 9.2%)
NCT05323734 · Phase 3 · registry result, not featured evidence
somnolence 40% (placebo 27.3%)
aggression 20% (placebo 9.1%)
agitation 20% (placebo 0%)
NCT03865732 · Phase 2 · registry result, not featured evidence
High
somnolence 37.5%
hypercaprnia 25%
hypocalcaemia 25%
NCT03350035 · Phase 2 · registry result, not featured evidence
Low
hypotension 40%
haematuria 20%
pain 20%
NCT03350035 · Phase 2 · registry result, not featured evidence
Medium
hypokalaemia 25%
pain 25%
pneumonia 25%
NCT03350035 · Phase 2 · registry result, not featured evidence
pyrexia 71.4%
upper respiratory tract infection 42.9%
vomiting 42.9%
NCT02358538 · Phase 2 · registry result, not featured evidence
dizziness 50%
sinusitis 50%
somnolence 50%
NCT02358538 · Phase 2 · registry result, not featured evidence
fungal infection 20%
hypersomnia 20%
seizure 20%
NCT02358538 · Phase 2 · registry result, not featured evidence
pyrexia 63.6%
somnolence 54.5%
fatigue 36.4%
NCT02358538 · Phase 2 · registry result, not featured evidence
headache 21.1%
convulsion 16.3%
fatigue 16.3%
NCT00512317 · Phase 2 · registry result, not featured evidence
headache 18.2%
irritability 18.2%
aortic aneurysm 9.1%
NCT01002820 · Phase 2 · registry result, not featured evidence
dizziness 16.3% (placebo 8.2%)
fatigue 16.3% (placebo 8.2%)
somnolence 13.3% (placebo 2%)
NCT00465517 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.
  2. bPopulation comparability has not been reviewed for 12 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Clobazam (Onfi)

Drop Seizure -41.2% (n=53) vs -12.1% (n=57) placebo @ 12wklow dose
percent change · % of baseline
Maintenance
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 41.2 Percent Reduction as posted
show 11 more results
-49.4% (n=58) vs -12.1% (n=57) placebo @ 12wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 49.4 Percent Reduction as posted
-68.3% (n=49) vs -12.1% (n=57) placebo @ 12wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 68.3 Percent Reduction as posted
-47.8% (n=53) vs -18.6% (n=57) placebo @ 4wk*low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 47.8 Percent reduction as posted
-58.9% (n=58) vs -18.6% (n=57) placebo @ 4wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 58.9 Percent reduction as posted
-71% (n=49) vs -18.6% (n=57) placebo @ 4wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 71 Percent reduction as posted
-44.1% (n=52) vs -21.1% (n=47) placebo @ 8wk*low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 44.1 Percent reduction as posted
-38.8% (n=53) vs -21.1% (n=47) placebo @ 8wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 38.8 Percent reduction as posted
-64.9% (n=44) vs -21.1% (n=47) placebo @ 8wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 64.9 Percent reduction as posted
-31.8% (n=51) vs 0.1% (n=44) placebo @ 12wk*low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 31.8 Percent reduction as posted
-56% (n=46) vs 0.1% (n=44) placebo @ 12wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 56 Percent reduction as posted
-68% (n=42) vs 0.1% (n=44) placebo @ 12wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 68 Percent reduction as posted
CGI-I 2 score
absolute value · score
No placebo or comparator arm
NCT03371836 · Phase 4 · registry result, not featured evidence

Ganaxolone

Seizure 50 28.1% (n=178) vs 22.7% (n=172) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 · converted to % from 50 Participants as posted
Seizure Free 0.05 vs 0.03 placebo months @ 14wk
absolute change · months
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 · converted to months from 1.47 days as posted
show 1 more result
0.05 vs 0.04 placebo months @ 14wk*
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 · converted to months from 1.63 days as posted
Seizure Frequency -1.46 vs -0.33 placebo per 28 day @ 14wk
absolute change · per 28 day
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 1 more result
-1.67 vs -0.64 placebo per 28 day @ 14wk
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Seizure-free 1.12% (n=178) vs 0% (n=172) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
at Least One Seizure Free Period 17.98% (n=178) vs 18.02% (n=172) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Time Spent Seizure-free 24% (n=178) vs 17.58% (n=172) placebo @ 14wk
absolute value · percentage points
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
SE Cessation 30 Min 79.59% (n=49) vs 12.77% (n=47) placebo @ 0.003wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
SE no Progression to IV Anesthesia 36 h 63.27% (n=49) vs 51.06% (n=47) placebo @ 0.2143wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
SE no Progression to IV Anesthesia 72h 51.02% (n=49) vs 46.81% (n=47) placebo @ 0.4286wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
Time to SE Cessation 0.07 vs 2.85 placebo hours
absolute value · hours
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
Treatment Escalation 24 h 55.1% (n=49) vs 80.85% (n=47) placebo @ 0.1429wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
Time to Treatment Escalation 5.42 vs 2.32 placebo hours
absolute value · hours
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3

+ 41 further endpoints in the CSV export.

Developmental and Epileptic Encephalopathies

Shared mechanism: GABA-A receptor · full Developmental and Epileptic Encephalopathies pipeline

Clobazam (Onfi)

Marketed by Lundbeck LLC and partners

Approved in Developmental and Epileptic Encephalopathiessmall molecule
Reliable signal

NCT00518713 · Phase 3 · completed

The study randomly assigned 238 participants to low-, medium-, or high-dose clobazam or placebo, with participants, care providers, and investigators masked to treatment. Its clinical primary endpoint—percent reduction in drop seizures—was statistically better than placebo for all three doses, supporting a strong evidence grade.

Reported efficacy

Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) (met)

Result source: NCT00518713

Ganaxolone

Marketed by Immedica Pharma AB

Approved in Developmental and Epileptic Encephalopathiessmall molecule
Partial signal

NCT03572933 · Phase 3 · completed

Marigold was a randomized, double-blind, placebo-controlled Phase 3 trial in 101 patients aged 2 to 21 with CDKL5 deficiency disorder. The primary endpoint was the percentage change in 28-day major motor seizure frequency over 17 weeks: -30.7% with ganaxolone vs -6.9% with placebo (p=0.0036), so the primary was met. Source: the peer-reviewed paper (Knight et al., Lancet Neurol 2022).

Reported efficacy

Summary of 28-day Seizure Frequency for Major Motor Seizure Types (End of the double-blind 17 week treatment period): Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022). (met)

Result source: NCT03572933

Results for Developmental and Epileptic Encephalopathies

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Clobazam (Onfi)
Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) NCT00518713 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ganaxolone

Seizure Frequency Per 45.03 vs 55.5 placebo per day @ 17wk
absolute value · per day
17 week-post baseline phase (Median)
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3
Seizure-free 32.29 vs 36.17 placebo % of time @ 17wk
absolute value · % of time
17-week-Post-Baseline Phase
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3
Longest Seizure Free Interval 0 vs -0.15 placebo months @ 17wk
absolute change · months
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3 · converted to months from -0.02 days as posted
Available safety results

Ganaxolone

Dropout rate
4%
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3
Discontinued due to AEs
2%
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3
Serious AEs
12%
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3
Most frequent reported AEs
somnolence 36% (placebo 15.7%)
pyrexia 18% (placebo 7.8%)
seizure 14% (placebo 17.6%)
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clobazam (Onfi)'s landscape · Ganaxolone's landscape